Smith & Nephew plc (LON:SN) Receives GBX 1,381.33 Average Price Target from Brokerages

Smith & Nephew plc (LON:SN) has been assigned an average recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is GBX 1,381.33.

Several research firms recently commented on SN. Citigroup lifted their price objective on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a report on Friday, October 31st. Royal Bank Of Canada downgraded shares of Smith & Nephew to a “sector perform” rating and dropped their price target for the company from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Finally, Panmure Gordon reissued a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a report on Tuesday, December 9th.

Smith & Nephew Trading Down 0.9%

Smith & Nephew stock opened at GBX 1,258 on Friday. The business has a 50 day simple moving average of GBX 1,253.76 and a two-hundred day simple moving average of GBX 1,277.23. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The company has a market cap of £13.79 billion, a price-to-earnings ratio of 45.29, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insiders Place Their Bets

In other news, insider Deepak Nath sold 1,240 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total transaction of £15,586.80. Corporate insiders own 0.19% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.